Sanofi Goes Public With Hostile Medivation Bid

Following weeks of speculation, Sanofi has gone public with its hostile offer for Medivation. Analysts are all in agreement that the deal would make "strategic sense" for Sanofi, but it's likely other suitors will throw their hats into the ring.

The offer for Medivation follows CEO Olivier Brandicourt's reorganization (Also see " Brandicourt's 'Big Reveal' Falls Flat For Sanofi " - Scrip, 10 November, 2015.) of Sanofi in which oncology is one of the businesses where he plans to build a competitive position.

Sanofi says it made a non-binding proposal to acquire San Francisco-based Medivation Inc. for $52.50 per share, an all-cash transaction...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category